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nterventional Atrial Septal Defect Closure
sing a Totally Bioresorbable Occluder Matrix
evelopment and Preclinical Evaluation of the BioSTAR Device
hristian Jux, MD,* Harald Bertram, MD,† Peter Wohlsein, DVM,‡ Michael Bruegmann, DVM,‡
homas Paul, MD, FACC*
oettingen and Hannover, Germany
OBJECTIVES We sought to test the hypothesis that interventional atrial septal defect (ASD) closure can be
performed safely and effectively using a bioresorbable occluder matrix.
BACKGROUND The ideal septal occluder scaffold should promote the healthiest and most complete healing
response while eventually facilitating the full resorption of the material and leaving “native”
tissue behind, thus minimizing the potential for future complications from chronic foreign
body and maintaining the possibility for later unobstructed transseptal access to the left
atrium.
METHODS The STARFlex occluders (NMT Medical Inc., Boston, Massachusetts) were modified by
substituting the conventional polyester fabric for a bioengineered, acellular type-I collagen
matrix derived from porcine submucosa with a heparin-coated surface (BioSTAR occluder,
NMT Medical Inc.). Comparative transcatheter closure of ASDs was performed in young
sheep (n  36). Gross pathology and histopathology were obtained after follow-up periods
ranging from 7 days to 2 years.
RESULTS The STARFlex (control) devices were encapsulated time-dependently by ingrown fibrous
tissue. Histology showed a mild but chronically persisting foreign body reaction. By contrast,
BioSTAR devices exhibited a mild-to-moderate transient cellular immune response. Heparin
coating of the BioSTAR surface improved the biocompatibility of the device by reducing
surface thrombogencity. A remodeling process of the collagen scaffold, starting after 30 days
in vivo, resulted in the full replacement of the matrix by host tissue after 2 years of follow-up.
CONCLUSIONS The BioSTAR device is the first septal occluder with a totally bioresorbable matrix that is
fully replaced by host tissue during the healing process. The promising results of this study
support testing of the BioSTAR device in clinical trials. (J Am Coll Cardiol 2006;48:161–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.057© 2006 by the American College of Cardiology Foundation
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nranscatheter closure of atrial septal defects (ASDs) has
ecome a routine treatment modality for children as well as
lder individuals. The permanent implant is expected to
ersist for the natural life expectancy of some 70 or 80 years
n the young recipients. However, the device itself may be
ispensable once the defect is closed and covered by a
omplete and firm layer of ingrown, endogenous “repair”
issue. This thought led us to the idea of a biodegradable
ccluder matrix: an absorbable scaffold that acts as a
emporary guide rail for the ingrowing host tissue from the
efect edge to cover the device and thus the defect under-
eath. The ideal bioresorbable septal occluder scaffold
hould promote the healthiest and most complete healing
esponse possible while eventually facilitating the full re-
orption of the material, leaving “native” tissue behind and
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006, accepted February 14, 2006.inimizing the potential for future complications while
roviding the possibility of later unobstructed transseptal
ccess.
Despite considerable differences between the designs of
he various septal occluder implants, all current commer-
ially available devices consist of a metal framework and a
ynthetic fabric. Studies in experimental animals have char-
cterized the histologic features and time course of the
ealing response and tissue ingrowth onto the device after
mplantation (1–7).
Although potential short- and mid-term complications
uch as residual shunts, thromboembolism, friction lesions,
erforations, metal fractures, and rhythm disturbances have
een well described (8–11), the long-term potential for
dverse effects over several decades remains to be deter-
ined. At the same time, technologies are just now evolving
or the treatment of left-sided heart disease, including
ercutaneous heart valve repair or replacement, arrhythmia
tudies, and therapies (e.g., pulmonary vein exclusion and
eft atrial appendage closure). An increasing proportion of
he young population is likely to benefit from these tech-
ologies in the future. The maintenance of an unobstructed
rans-septal access to the left atrium is of paramount
i
b
a
c
d
m
M
A
(
a
f
d
p
fi
(
s
w
s
s
t
N
n
s
b
a
p
s
T
f
t
t
p
c
w
w
A
c
3
a
(
(
I
d
v
u
v
c
y
m
i
b
w
C
C
t
a
1
i
G
l
F
i
h
162 Jux et al. JACC Vol. 48, No. 1, 2006
ASD Closure Using a Totally Resorbable Matrix July 4, 2006:161–9mportance for these interventional procedures, which may
e hampered by metal-rich devices and synthetic fabrics.
The aim of this preclinical feasibility study was to provide
proof of the concept of biodegradable interventional ASD
losure devices and to assess the efficacy and safety of a
egradable occluder matrix in an experimental animal
odel.
ETHODS
SD occluder devices. CardioSEAL STARFlex devices
NMT Medical Inc., Boston, Massachusetts), consisting of
MP35N stainless steel framework and a knitted polyester
abric, served as control devices (Fig. 1A). In BioSTAR
evices (NMT Medical Inc.) with bioresorbable fabric, the
olyester was substituted by a bioengineered, highly puri-
ed, acellular matrix consisting primarily of type I collagen
Organogenesis Inc., Canton, Massachusetts). Figure 1B
hows the BioSTAR device after rehydration of the matrix
ith saline. This biological matrix was derived from porcine
ubmucosa. Briefly, porcine small intestine is mechanically
tripped to obtain the tunica submucosa and remove the
unica mucosa as well as tunica muscularis and serosa.
on-collagenous components such as cells, cellular debris,
ucleic acids, lipids, and other extracellular matrix proteins
uch as glycosaminoglycans and proteoglycans are removed
y treatment of the tissue with alkali, chelating agents,
cids, and salts. This detergent- and enzyme-free method
reserves the structural integrity, cell compatibility,
trength, and bioremodelability of the collagen matrix (12).
igure 1. CardioSEAL device with STARFlex self-centering composed of
Abbreviations and Acronyms
ASD  atrial septal defect
ICE  intracardiac echocardiography
ICL  intestinal collagen layers replaced by a tissue engineered biodegradable porcine intestinal collagen lay
eparin coating is applied to the BioSTAR surface. It retains the same wire frahe purified intestinal collagen layer (ICL) is then rein-
orced by bonding several collagen layers together using a
hermal bonding technique. The thickness of ICL used in
his study was 150 to 200 m. After the suture of the ICL
atches onto the device framework, the fabric was heparin-
oated by a heparin benzalkonium chloride dip. Two devices
ere left without a heparin coating. Devices were sterilized
ith gamma irradiation at 25 kGy.
nimal model/defect creation. Atrial septal defects were
reated in young female black-headed mutton sheep (n 
6, mean body weight 32  5 kg) by trans-septal puncture
nd subsequent balloon dilation of the interatrial septum
1,13) under fluoroscopy and intracardiac echocardiography
ICE) control using the AcuNav system (Acuson, Siemens
nc., Mountain View, California). Anesthesia was intro-
uced by xylazine 0.4 mg/kg intramuscularly and an intra-
enous bolus infusion of 10 mg/kg ketamin. Animals
nderwent endotracheal intubation and were mechanically
entilated with isofluorane and oxygen/room air. Electro-
ardiogram, heart rate, respiratory rate, transcutaneous ox-
gen saturation, tidal volume, and end-tidal CO2 were
onitored throughout the procedure.
Following trans-septal puncture, a defect within the
nteratrial septum (Fig. 2A) was created by subsequent
alloon dilation of the interatrial septum using balloons
ith diameters of 6, 10, and 15 mm, respectively (Opta Pro,
ordis Europe N.V., Roden, the Netherlands; and Balt
BV, Montmorency, France) over a guidewire inserted into
he left atrium or a pulmonary vein. Heparin (200 U/kg
fter trans-septal puncture) and antibiotics (flucloxacillin
.5 g at the start of the procedure) were administered
ntravenously.
All animals received humane care in compliance with the
uide for the Care and Use of Laboratory Animals pub-
ished by the U.S. National Institutes of Health (NIH
P35n wire framework and a knitted polyester fabric (A). The fabric scaffoldan M
er (ICL) in the BioSTAR septal repair implant (B). An ionically bound
mework as the STARFlex device.
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July 4, 2006:161–9 ASD Closure Using a Totally Resorbable Matrixublication no. 85-23, revised 1996). The study was ap-
roved by the local governmental animal ethics committee.
evice implantation/defect closure. After allowing for
ealing of the created ASD edges for two to three weeks,
nimals were divided randomly into two groups. Defect
losure was performed using either conventional 23-mm
TARFlex devices (control group, total n  10) or 23-mm
ioSTAR devices (total n 26), respectively. Animals were
nesthetized as described earlier. Before defect occlusion,
eparin (200 units/kg intravenously) and antibiotics (flu-
loxacillin 1.5 g intravenously) were administered and bal-
oon sizing of the defect was performed (Arrow, Reading,
ennsylvania) by ICE using color Doppler to assess for stop
f flow. All devices were deployed transvenously through a
0-F–long Mullins-type transseptal sheath (Cook Inc.,
jaeverskov, Denmark) under fluoroscopy and ICE control
s described previously (14). Color Doppler was used to
ssess potential residual shunting. Animals did not receive
ny anticoagulation during follow-up.
evice explantation/macroscopic and histologic exami-
ation. One day before sacrifice of animals with more than
even days of follow-up, device position was confirmed by
oth fluoroscopy and ICE control under general anesthesia
s described earlier. A color Doppler examination was
erformed to assess residual shunting. The degree of resid-
al shunts was quantified according to the protocol pub-
ished by Boutin et al. (15). Animals from both groups were
acrificed 7 days, 30 days, 90 days, 180 days, 1 year, and 2
ears, respectively, after defect closure (2 STARFlex control
evices and 4 BioSTAR devices per time point). The 2-year
ollow-up group consisted of 4 BioSTAR devices only; in
he 7-day group 2 BioSTAR devices without heparin
oating were added.
Before sacrifice, each animal received an intravenous
ose of heparin (400 U/kg body weight) to prevent
ostmortem clot formation on the device, followed by a
ethal injection of pentobarbital. Complete autopsy was
erformed in each of the animals by two veterinary
igure 2. Interventionally created atrial septal defect (A) before closure us
he BioSTAR matrix showed an excellent echogenicity during and immed
trium.athologists. The hearts and adjacent vessels were in- vpected for the gross appearance of the implanted device
nd then fixed in alcoholic formaldehyde (two parts
thanol 95%, one part formaldehyde [40% gas by weight]
vol/vol]) for 48 h. In all animals, sections from 6 to 8
epresentative locations from the right and left atrial wall
ncluding the device (3 or 4 from the distal and 3 or 4
rom the proximal umbrella, respectively) and from both
entricular and septal myocardium were taken. Tissue
amples were embedded in paraffin wax, serially sec-
ioned, and stained with hematoxylin and eosin (general
tain and evaluation of cellularity) or elastica van Gieson
elastic fibers). All gross and microscopic specimens were
eviewed by two experienced veterinary pathologists
P. W. and M. B.).
tatistics. A two-tailed unpaired Student t test was used
or comparison of the means of defect sizes and device size
o defect size ratios between the two device groups. A value
f p  0.05 was considered statistically significant.
ESULTS
echnical aspects. All animals survived defect creation
nd the defect closure procedures as well as follow-up
eriods uneventfully. Interventionally created ASDs mea-
ured between 6 and 13 mm by two-dimensional echo
without stretching) and between 11 and 14 mm in diameter
s determined by balloon sizing immediately before defect
losure. The device-to-defect ratio thus varied between 1.6
nd 2.1 with no statistically significant difference between
he two groups. The STARFlex and BioSTAR devices were
uccessfully implanted in all sheep. The technical handling
f the BioSTAR devices did not differ significantly from
hat of the control devices. Likewise, no difference was
xperienced in the behavior of the BioSTAR device during
oading, delivery, (re)positioning, or release of the device.
chogenicity of the collagen matrix as assessed by ICE was
omparable to that of the polyester fabric, allowing for clear
ioSTAR or STARFlex (control) devices under intracardiac echo control.
after device deployment (B). Ao  aorta; LA  left atrium; RA  righting B
iatelyisualization of the device during deployment (Fig. 2B).
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ASD Closure Using a Totally Resorbable Matrix July 4, 2006:161–9In the 30-day follow-up groups, one of the four
ioSTAR devices and both STARFlex devices showed
rivial residual shunts as assessed by color flow Doppler
sing ICE. In the 90-day follow-up groups, none of the
our BioSTAR devices (but one of the two STARFlex
evices) showed a trivial residual shunt. No residual
hunting was observed in the 180-day and 1- and 2-year
ollow-up groups. All except one of the residual shunts
in a 30-day STARFlex explant) were confirmed later at
ostmortem examination. In all animals with residual
eakage, a probe patent shunt was found at the margin of
he device where the fabric was not firmly attached to the
eptum, resulting in space between fabric and septal wall.
ffect of heparin coating. Early thrombogenicity of the
urface of the devices was compared after seven days in vivo.
eparin-coated BioSTAR devices showed considerably less
eposition of blood-derived material on their surfaces than
TARFlex control devices and uncoated BioSTAR devices
Figs. 3A to 3F). Histologic workup of these devices
onfirmed the presence of less friable material consisting of
eposited plasma proteins and blood cells on heparin coated
ioSTAR devices (Figs. 3G to 3I). Thus, the defects
overed by these devices could still be seen owing to the
igure 3. Comparison of the healing response to STARFlex (A, D, G), B
urface (C, F, I) after 7 days in vivo. Significantly more deposits are found o
ioSTAR devices compared to heparin coated BioSTAR devices. The his
atrix ) and the deposition of plasma proteins and blood cells on theeparin-coated BioSTAR devices. Top row  right atrium; middle row  left a
spect, Histo  representative histology. H and E staining. Original magnificaransparency of the matrix (Figs. 3C and 3F). Very early
igns of a beginning neo-endothelialization were observed
n the form of a cellular monolayer on the surface of these
evices (Fig. 3I).
ross pathology. On gross inspection all devices were
acroscopically intact. There were no metal arm fractures
nd no adverse effects from the centering spring. No
ignificant compromise of blood flow at the pulmonary or
ystemic veins or at the heart valves was observed by
efore-sacrifice ICE, fluoroscopy, or postmortem inspection
n any of the animals.
Conventional STARFlex devices were almost completely
overed, except for the central pin and the metal arms, by a
hiny, glistening surface layer through which the polyester
abric could be seen after 30 days in vivo (Fig. 4A). Devices
ith a longer follow-up in vivo showed a small amount of
hitish, dull tissue underneath a complete glistening surface
ayer. Although the thickness of the tissue layer between
urface and polyester fabric increased somewhat after 180
nd 360 days compared with 90 days in vivo, the fabric
emained visible through this tissue. The metal framework
f the device was covered only by a shining film after 90
ays. However, after 180 days in vivo, the ingrown tissue
AR devices without heparin coating (B, E, H) and with heparin-coated
right (A, B, C) and left atrial surface (D, E, F) of STARFlex and uncoated
y (G, H, I) shows the level of the scaffold (<  polyester, **  collagen
ce (arrows). Early signs of neo-endothelial formation are observed onioST
n the
tolog
devitrium; bottom row  histology. RA  right atrial aspect, LA  left atrial
tion 10 (F, G), 20 (H).
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July 4, 2006:161–9 ASD Closure Using a Totally Resorbable Matrixigure 4. Comparison of the healing response to STARFlex and BioSTAR devices after 30 days to 2 years follow-up. Photos of the gross appearance of
he devices were taken immediately after sacrifice and dissection of the hearts. For comparison, the right atrial surface of STARFlex control (A, C, E, G)
r BioSTAR devices (B, D, F, H, I) is always shown. The orifice of the coronary sinus is located at the bottom in each of the pictures. Scale in millimeters.
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ASD Closure Using a Totally Resorbable Matrix July 4, 2006:161–9overed the straight parts of the metal arms, leaving merely
he central pin and shoulder and elbow joint coils unincor-
orated (Figs. 4E and 4G).
Occasionally an infolding (“scalloping”) of the edges of
he polyester fabric was observed, which prevented a smooth
ontinuity between the devices and the adjacent atrial tissue.
one of the devices showed any evidence of thrombus
ormation.
At gross pathology, BioSTAR devices showed a complete
hining, glistening coverage on the device after 30 days in
ivo (Fig. 4B). Compared to STARFlex control devices,
ioSTAR occluders showed a significantly more thorough
overage of the device by grayish-white tissue at any time of
ollow-up during the entire study (Fig. 4).
Infolding (“scalloping”) of the edges was not observed in
he BioSTAR explants. Rather, in comparison to control
evices, the BioSTAR devices exhibited a smoother inter-
ace toward the adjacent atrial tissue. However, in some
ccluders there was a tendency for contraction in the middle
f the edges of the ICL matrix. Again, none of the devices
howed any evidence of thrombus formation.
istology of healing response and bioresorption of the
ccluder matrix. The histologic examination of STARFlex
evices after 30 days in vivo revealed a low amount of loosely
rranged and poorly vascularized young granulation tissue
overed by neo-endothelium (Fig. 5A). At later stages
uring follow-up, the ingrown tissue on the polyester
urface was found to be organized in a longitudinal orien-
igure 5. Histology of the healing response to STARFlex devices. Ingrow
ound after 30 days in vivo. Newly formed fibrous tissue in parallel orien
ormation underneath the neo-endothelium with more loosely arranged
hronically persisting immune response with infiltration of some lymphocytes (B
een around the polyester fibers. H and E staining. Original magnification 2.ation parallel to the surface of the device (Figs. 5B and 5C).
fter 180 days in vivo, encapsulation of the polyester was
bserved. The typical histologic finding consisted of a
ilayered texture: dense avascular connective tissue was
bserved immediately underneath the neo-endothelium,
hereas more loosely arranged fibers containing capillaries
nd small vessels were found in deeper segments of the
ngrown tissue (Fig. 5C). The amount of newly formed
ollagen and elastic fibers increased over time.
Directly adjacent to the polyester, there was a mild
nfiltration with lymphocytic cells, which persisted during
he later stages of follow-up. Consistently, macrophages and
ultinucleated foreign body giant cells were found neigh-
oring the polyester fibers (Fig. 5D). Histologic workup of
ioSTAR devices explanted after 30 days in vivo showed
omplete neo-endothelial coverage that was in smooth
ontinuation with the atrial tissue surrounding the previous
efect. Multiple layers of young granulation tissue were
ound between the surface and the collagen implant (Figs.
A and 6B). Although largely intact, focal areas of the
ioSTAR matrix exhibited the first signs of disintegration.
ongitudinal splits and fraying at the terminal edges of the
ollagen matrix allowed for infiltration of the matrix with
broblastic and mononuclear lymphoid cells (Figs. 6A to
D). Starting after one month in vivo, phagocytosis of the
atrix by macrophages and multinucleated giant cells was
bserved in direct contact with the collagen (Fig. 6C). The
tissue from the defect edges (left margin in A) covering the polyester was
to the device surface (B, after 90 days in vivo) led to a dense avascular
and capillaries in deeper layers (C, after 180 days in vivo). A mild butth of
tation
fibersto D) and foreign body giant cells (arrows in D, after 1 year in vivo) is
5 (A), 5 (B), 10 (C), 20 (D).
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July 4, 2006:161–9 ASD Closure Using a Totally Resorbable Matrixhagocytic activity continued (Figs. 6F and 6J) until full
esorption of the implanted matrix was achieved.
Three months after implantation, progressive stages of
ioSTAR matrix disintegration were found. Thicker stripes
f fibrous granulation tissue extended into the collagen
bers, pushing apart detached collagen fragments. In some
ections, the matrix layer appeared discontinuous (Figs. 6E
nd 6F). Compared with earlier explants, the sub-
eoendothelial fibrous tissue was thicker, arranged in a more
ompact formation, and less rich in fibroblastic cells. Small
essels or capillaries and newly formed collagen fibers were
bserved within deeper layers of this tissue.
At later stages during follow-up, after 6 to 12 months in
ivo, the ICL matrix had lost its structural continuity (Figs.
G and 6I), although with some inter- and intraindividual
ariability; many sections exhibited only collagen fragments.
n some sections, focal lymphocytic infiltration was found in
he vicinity of the matrix (Fig. 6H). However, these
ymphocytic infiltrations were always circumscribed and not
een in any area where the collagen had undergone full
egradation.
After two years in vivo, the implanted collagen matrix was
ompletely resorbed and fully replaced by autologous host
issue in 63% of all specimen locations (i.e., all serially cut
igure 6. Histology of the healing response to BioSTAR devices. After 3
raying and longitudinal splitting of the matrix (A and B, enlarged detail in
ells) and infiltration by host fibrous cells (D) occurred. Progressive struc
E to J, level of residual collagen, arrowheads). Occasionally, sections show
atrix. After 1 year, sections showed remnants of the occluder matrix (I, e
ost tissue after 2 years in vivo (K, enlarged detail in L). *Rim of ASD. H
5 (E, I, L), 10 (A, B), 20 (F, H, J), 40 (C, D).ections in these locations were free of previously implanted mollagen). In the remaining locations, only a few sections
howed small remnants or tiny spots of the previously
mplanted ICL material. On the basis of these findings, it
as calculated that approximately 90% of all implanted ICL
aterial had been resorbed after two years in vivo. In
omparison to the histology of earlier stages, the autologous
epair tissue appeared relatively poor in fibroblastic cells but
icher in connective fiber content. Especially the amount of
ewly formed elastic fibers increased over time (elastica van
ieson staining) (Figs. 6K and 6L). However, no fibrous
apsule formation was found.
ISCUSSION
echnical aspects of the BioSTAR device. The general
andling of the BioSTAR device did not significantly differ
rom that of the STARFlex control device, although the
perators described the BioSTAR device behavior as some-
hat “softer” compared with the STARFlex. Intracardiac
chocardiography was used to guide the interventional
efect creation as well as defect closure because the sheep
natomy does not allow for adequate transesophageal im-
ging of the interatrial septum. The BioSTAR occluder
s in vivo, first signs of remodeling of the collagen matrix were observed:
eginning of phagocytic resorption (C, arrows point at multinucleated giant
isintegration and absorption of the collagen matrix proceeded over time
rcumscribed lymphocytic infiltrates (H, arrowhead) in close vicinity to the
ed detail in J). The implanted collagen matrix was completely replaced by
E and elastica van Gieson staining. Original magnification 2.5 (G, K),0 day
C), b
tural d
ed ci
nlargatrix showed appropriate echogenicity, allowing for pre-
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ASD Closure Using a Totally Resorbable Matrix July 4, 2006:161–9ise visualization by ICE during implantation and follow-up
tudies.
ealing response to control and BioSTAR devices. The
ealing response to STARFlex control devices described in
his study was uncomplicated and resembled that described
reviously by others both in experimental animals (1,2) and
umans (16). Complete neo-endothelialization in all sec-
ions was observed after three months in vivo. Ingrowth of
ranulation tissue started in the device periphery and pro-
eeded preferably along the framework arms toward the
entral parts of the device. The thickness of the tissue layer
n the device surface increased over time, finally reaching a
teady state after one year where only some arm joints
emained unburied by tissue. A mild to moderate but
ersistent foreign-body reaction was noted in our study as
ell as in previously reported studies close to the polyester
abric (2,16).
Intestinal collagen layer, which has been used as the
ccluder scaffold on BioSTAR devices, is a highly purified
cellular bioengineered type I collagen derived from porcine
ubmucosa. It is gradually resorbed by the host organism
nd subsequently replaced by host tissue (12,17). Following
xtensive experimental investigations, porcine small intesti-
al submucosa has been successfully used clinically in
arious fields of soft tissue augmentation, to treat hernias
nd in tendon repair (18–20), stress urinary incontinence
21), leg ulcers (22), plastic surgery (23), and vascular
urgery (24).
The BioSTAR devices showed an accelerated healing
esponse compared with the control implants. First signs of
single-layer neo-endothelium were observed already after
days in vivo (Fig. 3I). A state of complete neo-
ndothelialization was observed after 30 days (Figs. 6A and
B). This early neo-endothelialization argues in favor of the
iocompatibility of the BioSTAR device. A layer of in-
rown young granulation tissue that was in smooth conti-
uity with the adjacent atrial tissue was found on the
ioSTAR devices. The BioSTAR device showed an excel-
ent efficacy in ASD closure. Although animal numbers
nvolved in this study are too low to reach statistical power,
he observed lower incidence of early residual leakage with
he BioSTAR device is potentially attributable to the better
lignment of the device to the surface of the atrium.
urthermore, the fact that the BioSTAR matrix is a foil
ather than a knitted mesh may also decrease early residual
hunting as observed as “foaming” through the polyester.
owever, larger scale clinical studies will be needed to verify
his hypothesis.
hrombogenicity of control and BioSTAR devices. Con-
act between blood and a foreign material is known to
ctivate the coagulation and complement systems. Throm-
us formation and thromboembolism due to the thrombo-
enicity of the implanted occluder surface are rare but
linically well-described potential complications. The vast
ajority of thrombi formations on ASD occluder devicesccur in the early vulnerable phase before a protective fomplete neo-endothelialization on the device surface has
eveloped (8,25). The BioSTAR devices as used in this
tudy were heparin-coated, which led to a reduced throm-
ogenicity of their surface. The amount of blood cells and
eposited plasma protein on the surface after seven days in
ivo was significantly lower compared with both the un-
oated BioSTAR devices and the polyester matrix of con-
entional STARFlex devices. Heparin surface coatings have
een shown to reduce blood activation upon contact with
arious artificial surfaces, such as bypass tubings, intravas-
ular catheters, stents, and Nitinol devices (26–28). The
urface-bound heparin triggers a cascade of effects, includ-
ng the initial interaction between heparin and antithrom-
in, reducing fibronectin deposition, inhibition of comple-
ent and platelet activation, and reduction of an initial
nflammatory response (29–31).
mmunogenicity of control and BioSTAR devices. The
CL collagen matrix exhibited a surprisingly low immune
esponse, given its xenogenic origin. Whereas the polyester
abric showed a mild but chronically persisting foreign body
eaction, the BioSTAR matrix led to a transient, focally
ircumscribed mild-to-moderate lymphocytic immune re-
ponse. Cellular infiltration was not observed once the
mplanted collagen matrix had undergone full degradation.
he low immunogenicity may be explained by various facts.
irst, type I collagen, as the most abundant protein com-
onent of the extracellular matrix, is a highly preserved
rotein in evolution (32,33). Second, the particular cleaning
rocess of the porcine submucosa removes cells and cellular
ebris, to which most of the immunogenicity is attributed,
ithout damaging the native collagen structure (12,34,35).
inally, molecular studies showed that porcine small intes-
inal submucosa elicits a predominantly TH2-restricted
mmune response, consistent with a bioresorbable remodel-
ng reaction rather than a graft rejection (36).
iodegradability of the BioSTAR matrix. The unique
eature of the ICL matrix, however, is its biodegradability.
emodeling of the collagen matrix started after 30 days in
ivo with host cell infiltration. Autologous fibroblasts were
bserved to infiltrate the collagen implant, leading to the
eposition and rearrangement of new host collagen. After
80 days in vivo, a significant degree of degradation of the
atrix was obvious. Resorption of the material occurred by
hagocytosis. In addition, collagen is known to be metab-
lized by various endopeptidases such as matrix metallopro-
einases, serine, cysteine, and aspartic proteases (37).
hrough its ability to interact with the host, the purified
ollagen first acts as a scaffold for new tissue ingrowth. The
atrix assimilates with host tissue as it is initially aug-
ented by host tissue before it is resorbed, finally leaving
othing but autologous tissue behind.
onclusions. This study proves the feasibility of the con-
ept of biodegradable interventional ASD closure devices.
he BioSTAR device is the first septal occluder device with
totally biodegradable matrix. It is, therefore, a step awayrom a mere mechanical septal defect occluder toward a
s
l
f
f
t
c
a
r
s
i
s
A
T
a
w
R
p
M
D
g
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
169JACC Vol. 48, No. 1, 2006 Jux et al.
July 4, 2006:161–9 ASD Closure Using a Totally Resorbable Matrixeptal repair device. Although the BioSTAR device only
eaves a minimal amount of foreign material (i.e. the
ramework) behind, thus minimizing the potential risk for
uture complications from chronic foreign body and facili-
ating future trans-septal access to the left atrium, work is
urrently underway to develop a resorbable and fully retriev-
ble occluder framework. This research may eventually
esult in various totally bioresorbable cardiovascular devices.
Because of the promising results of this experimental
tudy, the BEST (Biostar Evaluation STudy) trial, the first
n human investigation of this new technology, has been
cheduled.
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